Climb Bio (CLYM) Cash from Financing Activities (2020 - 2026)

Climb Bio's (CLYM) quarterly Cash from Financing Activities came in at $5000.0 in Q1 2026, up 123.81% on a QoQ basis from -$21000.0 in Q4 2025.

Climb Bio (CLYM) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Climb Bio (CLYM) has 6 years of Cash from Financing Activities data on file, last reported at $5000.0 in Q1 2026.

  • Quarterly Cash from Financing Activities changed N/A year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16000.0 (down 100.01% YoY) and the FY2025 annual result came in at -$21000.0, down 100.02% from the prior year.
  • Cash from Financing Activities grew to $5000.0 in Q1 2026, from -$21000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $128.4 million in Q2 2024 to a low of -$21000.0 in Q4 2025.
  • A 4-year average of $13.2 million and a median of $32500.0 in 2023 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 534908.33% — and 2025, when it plunged 151.22%.
  • Tracing CLYM's Cash from Financing Activities over 4 years: stood at $288000.0 in 2023, then slumped by 85.76% to $41000.0 in 2024, then sank by 151.22% to -$21000.0 in 2025, then surged by 123.81% to $5000.0 in 2026.
  • The last three Cash from Financing Activities figures came in at $5000.0 (Q1 2026), -$21000.0 (Q4 2025), and $41000.0 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 2.42 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -6.05 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -207,909.22
7 Royalty Pharma 33.72 Bn 35.84 Bn - -273.15 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 36.24 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 27.18 Mn
10 Climb Bio 1.24 Bn 1.24 Bn - 103.70 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 103.70 Mn
Jun 30, 2026 103.70 Mn
Mar 31, 2026 5,000.00
Mar 31, 2026 5,000.00
Dec 31, 2025 -21,000.00
Dec 31, 2025 -21,000.00
Dec 31, 2024 41,000.00
Dec 31, 2024 41,000.00
Sep 30, 2024 2.27 Mn
Sep 30, 2024 2.27 Mn
Jun 30, 2024 128.40 Mn
Jun 30, 2024 128.40 Mn
Mar 31, 2024 15,000.00
Mar 31, 2024 15,000.00
Dec 31, 2023 288,000.00
Dec 31, 2023 288,000.00
Sep 30, 2023 528,000.00
Sep 30, 2023 528,000.00
Jun 30, 2023 24,000.00
Jun 30, 2023 24,000.00